If You Invested in Inhibitor Therap (INTI)

Inhibitor Therapeutics, Inc. (INTI) is a biotechnology company focused on the clinical development of itraconazole-based therapies in oncology. According to company communications, its primary development program centers on an itraconazole formulation for the treatment of basal cell carcinomas (BCCs) in patients with Basal Cell Carcinoma Nevus Syndrome (BCCNS), also known as Gorlin Syndrome, a rare hereditary cancer syndrome. The company’s shares are quoted on the OTCQB market under the symbol INTI.

Core focus: itraconazole in oncology

Inhibitor Therapeutics is developing a proprietary, patentable formulation of itraconazole for oncology indications. The company reports that itraconazole has a well understood safety profile and, based on data from a completed Phase 2b clinical study (the SCORING trial), demonstrated clinically meaningful efficacy in reducing BCC tumor burden in patients with Gorlin Syndrome. Inhibitor has engaged Avior Bio to develop a new formulation that will be bridged to both the formulation used in its completed clinical study and to generic itraconazole through a pharmacokinetic (PK) study.

The company has also entered into an exclusive, worldwide licensing agreement with Johns Hopkins University covering patents titled "New Angiogenesis Inhibitors" that list itraconazole as an active pharmaceutical ingredient with anti-angiogenic properties. The licensed field of use includes prostate cancer, basal cell carcinoma (including BCCNS), and lung cancer.

Basal Cell Carcinoma Nevus Syndrome (Gorlin Syndrome)

Company disclosures describe BCCNS as an orphan oncology disease affecting an estimated 11,000 patients in the United States. Patients may develop hundreds to thousands of basal cell carcinomas over their lifetimes. The current first-line treatment for BCCs on exposed areas such as the face and neck is Mohs surgery, which can become increasingly challenging and may lead to permanent scarring and disfigurement as patients undergo repeated procedures.

Inhibitor Therapeutics states that many patients with BCCNS are primarily concerned with the high number of surgical interventions and the resulting disfigurement. The company’s goal is to develop an oral therapy with acceptable toxicity that can reduce the number of lesions requiring scar-producing interventions, addressing what it characterizes as an unmet medical need for this patient population.

Clinical development and SCORING trial data

The Phase 2b SCORING trial conducted by Inhibitor Therapeutics evaluated oral itraconazole in patients with BCCNS. The company reports that the study assessed 477 pre-existing, surgically eligible target lesions across 38 patients. Each lesion represented a distinct basal cell carcinoma rather than a metastatic lesion, reflecting the unique nature of BCCNS where patients present with multiple primary tumors.

According to the company’s summary of trial outcomes, reductions of any size from baseline were reported in 399 of the 477 target lesions, 64 lesions showed no change, and 14 increased in size. A pre-defined clinically meaningful reduction of 30% or greater in lesion size was observed in 275 of the 477 lesions, and 130 lesions resolved completely. The company also notes that a subset of lesions was stabilized and that only one patient discontinued itraconazole due to progressive disease. The oral itraconazole regimen was described as generally well tolerated, with no treatment-related serious adverse events reported in the company’s release.

Inhibitor Therapeutics has convened a Scientific Advisory Board (SAB) composed of experienced Mohs surgeons and dermatologic oncologists. The SAB has been tasked with critically reviewing the final clinical outcomes of the SCORING trial to evaluate the clinical usefulness of itraconazole in BCCNS and to assess whether the data are sufficiently meaningful to support a potential New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA).

Regulatory pathway and FDA interactions

The company has submitted a Pre-Investigational New Drug (PIND) application for its itraconazole formulation for BCCs in BCCNS patients. This PIND has been reviewed by the FDA’s Division of Dermatology and Dentistry, with input from the Division of Oncology 3 where necessary. Inhibitor Therapeutics reports that it has received preliminary comments from the FDA providing guidance in preparation for a full Investigational New Drug (IND) application.

Inhibitor’s stated development plan includes three key steps: completing the new proprietary itraconazole formulation (including patent creation), conducting and compiling results from the bridging PK study to link the new formulation to both the prior clinical formulation and generic itraconazole, and preparing and submitting an IND to the FDA for review and guidance.

Scientific and mechanistic context for itraconazole

Inhibitor Therapeutics references published literature indicating that angiogenesis is a requirement for tumor growth and metastasis and that tumors can promote angiogenesis by secreting proangiogenic factors. The company cites work in which itraconazole is described as having anti-angiogenic properties and identifies the mitochondrial protein VDAC1 as a major target in endothelial cells. In the referenced studies, inhibition of VDAC1 by itraconazole is associated with changes in cellular energy balance, activation of AMP-activated protein kinase (AMPK), and inhibition of the mTOR signaling pathway, which is implicated in angiogenesis.

The company also refers to research using RNA sequencing to examine biological pathways driving BCC growth, noting that basal cell carcinomas showed increased expression of the mTOR pathway, which plays a role in regulating angiogenesis. Inhibitor Therapeutics positions its SCORING trial data as complementary to this literature, citing the observed lesion responses in BCCNS patients treated with itraconazole.

Collaborations and advisory relationships

Inhibitor Therapeutics reports an alliance with The Gorlin Syndrome Alliance, a non-profit patient advocacy organization focused on Gorlin Syndrome. The company notes that the Alliance conducted an externally led patient-focused drug development meeting, where many participants indicated that a reduction of at least 30% in tumor burden would represent a meaningful clinical endpoint, short of a cure.

The company’s Scientific Advisory Board consists of dermatologists and Mohs surgeons with extensive experience in skin cancer management, Mohs micrographic surgery, and clinical trials related to skin cancer. According to company releases, these advisors are affiliated with major academic medical centers and professional organizations and are engaged to review the Phase 2b clinical study report and assess the potential role of itraconazole as a therapeutic option for BCCNS.

Corporate agreements and equity incentives

In a reported Form 8-K, Inhibitor Therapeutics disclosed entering into a performance-based master services agreement with Frameshift Management, Inc. Under this agreement, Frameshift is to provide consulting services in biostatistics, regulatory matters, business development, and strategic consulting in support of the company’s programs in basal cell carcinomas in Gorlin Syndrome, utilizing the company’s proprietary new formulation of itraconazole. The agreement includes customary provisions regarding confidentiality, indemnification, intellectual property, data protection, termination rights, and compliance with applicable laws.

The same filing describes the approval of the Inhibitor Therapeutics, Inc. 2025 Equity Incentive Plan by the company’s Board of Directors. The plan allows for the grant of stock options, stock appreciation rights, restricted stock, restricted stock units, and other stock- or cash-based awards to eligible service providers, with administration by the Board or its committees. The plan includes a share reserve and requires shareholder approval within a specified period, with termination provisions if such approval is not obtained.

Position within biotechnology and research focus

Within the broader biotechnology landscape, Inhibitor Therapeutics presents itself as a research-driven company concentrating on itraconazole’s role in oncology, particularly in conditions characterized by extensive basal cell carcinoma burden. Its work spans clinical trial execution, regulatory engagement with the FDA, and scientific collaborations and licensing arrangements with academic institutions such as Johns Hopkins University.

By focusing on a rare hereditary cancer syndrome and leveraging existing pharmacologic knowledge of itraconazole, the company’s disclosures emphasize both the clinical data from its SCORING trial and the mechanistic rationale related to angiogenesis and mTOR pathway modulation. Investors and observers reviewing INTI can examine these elements through company press releases, scientific references cited by the company, and SEC filings that outline material agreements and incentive structures.